The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations

Published:2024-05 Issue: Volume:202 Page:113984
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schaper-Gerhardt Katrin,Gutzmer Ralf,Angela Yenny,Zimmer Lisa,Livingstone Elisabeth,Schadendorf Dirk,Hassel Jessica C.,Weishaupt Carsten,Remes Bernhard,Kubat Linda,Spassova Ivelina,Becker Jürgen C.

Publisher

Elsevier BV

Reference32 articles.

1. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma;Wolchok;J Clin Oncol,2022

2. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma;Robert;N Engl J Med,2019

3. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors;Tas;Melanoma Res,2017

4. The RANK/RANKL/OPG system and tumor bone metastasis: potential mechanisms and therapeutic strategies;Zhang;Front Endocrinol,2022

5. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab;Lacey;Nat Rev Drug Discov,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppressive tumor microenvironment in gastric signet-ring cell carcinoma;World Journal of Clinical Oncology;2024-09-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP